This test is changing the way depression is treated

Story excerpt provided by MarketWatch.

Written by Amy Hoak.

Many Americans suffer from depression at some point in their lives. The seriousness of the disease (untreated, it’s a top cause of suicides) is a reason why the U.S. Preventive Services Task Force recently recommended screenings for anyone 12 or older; screenings are often in the form of a questionnaire at the doctor’s office to help determine whether the patient is at risk.

Treating depression, however, can involve much trial and error when it comes to medications, as not everyone responds the same way to any particular drug.

But a company in Mason, Ohio (Assurex Health), is making advances in helping pinpoint the medicine best suited to an individual suffering from depression or another mental illness — by analyzing DNA swabbed from the inside of the patient’s cheek. The GeneSight test is based on technology licensed from the Mayo Clinic and Cincinnati Children’s Hospital Medical Center.

Click here to read the complete article.

Originally published February 17, 2016.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: